相关实验视频

Updated: Jul 19, 2025

A Method for Measuring RNA N6-methyladenosine Modifications in Cells and Tissues

A Method for Measuring RNA N6-methyladenosine Modifications in Cells and Tissues

Published on: December 5, 2016

在阿尔茨海默氏病中,N6-甲基氨酸 (m6A) 修饰对细胞表型的影响

Pengyun Ni¹, Kaiting Pan², Bingbing Zhao³

¹Department of Science and Education, Baoji Traditional Chinese Medicine Hospital, Baoji, Shannxi, P.R China.

|August 7, 2023

概括

这项研究确定了关键的N6-甲基氨酸 (m6A) 修饰基因和参与阿尔茨海默病 (AD) 病原发生的途径. 这些发现突出了AD治疗的潜在治疗点和药物.

科学领域:

神经科学是一个神经科学.
遗传学是一个遗传学.
分子生物学分子生物学

背景情况:

N6-甲基氨酸 (m6A) 修饰因其在神经退行性疾病中的关键作用而越来越受认可.
全基因组测绘揭示了与阿尔茨海默病 (AD) 相关的基因中显著的m6A甲基化.

研究的目的:

为了研究在阿尔茨海默氏病的发病过程中m6A修饰的枢纽基因和途径.
为了确定潜在的治疗化合物和大脑区域与AD治疗高基因表达.

主要方法:

对AD数据集的差异基因表达分析 (GSE5281,GSE48350).
功能丰富分析和路径分析 (KEGG).
蛋白质与蛋白质相互作用网络的构建和枢纽基因的识别 (STRING,Cytoscape,CytoHubba).
分析大脑组织中的枢纽基因表达 (HPA,Bgee) 和药物查 (cMAP).

主要成果:

在AD中鉴定了42个不同表达的m6A修饰基因 (20个上调,22个下调).
这些基因参与生物过程,如视网膜酸信号,DNA损伤反应和囊类型内酶活性,主要通过Hippo信号通路.
选了10个枢纽基因,并预测了10种具有AD潜在治疗作用的化合物.

结论:

生物信息分析揭示了m6A修饰基因在AD中的重要作用.
生物变化与视网酸,DNA损伤反应和通过Hippo信号通路的囊类型内酶活性有关.
已识别的枢纽基因 (SOX2,KLF4,ITGB4,CD44,MSX1,YAP1,AQP1,EGR2,YWHAZ,TFAP2C) 和潜在的药物为AD预后和治疗提供了新的方向.

更多相关视频

Characterizing RNA Modifications in Single Neurons Using Mass Spectrometry

Characterizing RNA Modifications in Single Neurons Using Mass Spectrometry

Published on: April 21, 2022

Author Spotlight: Exploring Sex-Specific Glial Signatures and Therapeutic Leads for Alzheimer's Disease

Author Spotlight: Exploring Sex-Specific Glial Signatures and Therapeutic Leads for Alzheimer's Disease

Published on: May 20, 2024

相关概念视频

Alzheimer's Disease: Overview

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...

RNA Editing

RNA Editing

RNA editing is a post-transcriptional modification where a precursor mRNA (pre-mRNA) nucleotide sequence is changed by base insertion, deletion, or modification. The extent of RNA editing varies from a few hundred bases, in mitochondrial DNA of trypanosomes, to a just single base, in nuclear genes of mammals. Even a single base change in the pre-mRNA can convert a codon for one amino acid into the codon for another amino acid or a stop codon. This type of re-coding can significantly affect the...

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

RNA Stability

RNA Stability

Intact DNA strands can be found in fossils, while scientists sometimes struggle to keep RNA intact under laboratory conditions. The structural variations between RNA and DNA underlie the differences in their stability and longevity. Because DNA is double-stranded, it is inherently more stable. The single-stranded structure of RNA is less stable but also more flexible and can form weak internal bonds. Additionally, most RNAs in the cell are relatively short, while DNA can be up to 250 million...